Amid the recent outbreak of Nipah virus in West Bengal, India, which the World Health Organization has classified as a lethal zoonotic virus with a fatality rate of 40% to 75% and for which there are currently no specific treatments or vaccines, the urgent global need for rapid, precise diagnostic and early warning capabilities within public health systems has been starkly highlighted. As a high-tech intellectual property capital operation platform with a long-standing focus on the life sciences sector, IVD MEDICAL Holding Limited ("the Company" or "IVD MEDICAL") consistently monitors global public health developments, leveraging its strategic positioning in pathogen molecular diagnostics and the AI healthcare ecosystem to provide continuous technical support for the containment of emerging infectious diseases. The Company's subsidiary, Shenzhen Tanhua Biotechnology Co., Ltd. ("Tanhua Biotech"), established through a strategic joint investment by IVD MEDICAL and the biotech unicorn Carboncloud Intelligent, is a high-tech enterprise dedicated to the molecular diagnostics field, integrating R&D, production, and technical services to offer comprehensive, one-stop molecular diagnostic solutions. Tanhua Biotech's core R&D team possesses extensive experience across in-vitro diagnostic reagent development, genomics, bioinformatics, and artificial intelligence, ensuring its technological solutions are both forward-looking and rapidly deployable through efficient collaboration and innovative management practices. The Company is pleased to announce that Tanhua Biotech has successfully developed a dual-platform detection solution for the Nipah virus, providing end-to-end technical support from rapid screening to precise source tracing. The dual-platform system comprises an Intelligent Fluorescent PCR Rapid Detection Platform and a High-Throughput Sequencing & Intelligent Analysis Platform. For the Intelligent Fluorescent PCR Rapid Detection Platform, Tanhua Biotech utilizes its self-developed AI primer design platform, which deeply integrates intelligent modules for gene retrieval, automated primer design, and multi-dimensional performance evaluation. Leveraging machine learning algorithms and a proprietary database of species-specific nucleic acid sequences, the platform efficiently identifies and targets conserved genomic regions of high-risk pathogens like the Nipah virus, enabling rapid and precise primer design and system optimization. This technological framework ensures high specificity and sensitivity while significantly improving amplification uniformity and suppressing primer-dimer formation, thereby enhancing the reliability of detection results. The "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" developed based on this platform features intelligent and user-friendly operation, highly efficient and accurate detection, and stable system compatibility. For the High-Throughput Sequencing & Intelligent Analysis Platform, Tanhua Biotech has constructed a localized pathogen sequencing solution covering the entire workflow from "wet-lab experiments to dry-lab analysis," based on next-generation sequencing technology. Relying on a proprietary and continuously updated multi-species pathogen genomic database (encompassing 18,628 pathogens including bacteria, viruses, fungi, and parasites), the system enables simultaneous detection and identification of the Nipah virus and other co-infecting pathogens. The system is supported by a self-developed intelligent microbial data analysis and reporting platform, integrating one-click bioinformatics analysis, automated report generation, and visualization functions, achieving a fully closed-loop process from sample reception to report issuance within 17 hours. This platform not only supports the rapid identification of common, rare, and novel pathogens but can also be applied to viral evolution tracking, transmission chain analysis, and public health risk assessment, providing molecular evidence and data insights for precise containment measures. The swift deployment of this Nipah virus detection capability not only demonstrates Tanhua Biotech's technical prowess but also represents a critical component of IVD MEDICAL's broader AI healthcare strategy advancement. As the Company steadily progresses with the acquisition of Ciming Health Checkup Technology Management Group Co., Ltd. (Stock Code: 300451.SZ) (relevant procedures are proceeding in an orderly manner), the Group is accelerating the construction of a next-generation public health containment paradigm centered on "AI Early Warning + Rapid Diagnosis + Ecosystem Synergy." The rapid response to the Nipah virus threat serves as a significant validation of IVD MEDICAL's integrated technological capabilities in managing public health emergencies. Looking ahead, building upon the "AI Early Warning + Rapid Diagnosis + Ecosystem Synergy" capabilities refined through such events, the Group is committed to building an intelligent public health surveillance system that is rapidly deployable and adaptable to various scenarios involving emerging infectious diseases and chronic disease management. This product launch and strategic exposition represent another manifestation of IVD MEDICAL's deepening commitment to its core paradigm of "Intelligent Capital Driving Sustainable Profitability from Knowledge." The Company will continue to leverage its three core pillars – K1 (IVD Distribution Network), K2 (IVD MEDICAL Ecosystem), and K3 (Capital Operations) – to persistently enhance the innovation efficiency and commercial value of enterprises within its ecosystem through technological integration, data synergy, and capital empowerment.